ATE552012T1 - Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff - Google Patents

Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff

Info

Publication number
ATE552012T1
ATE552012T1 AT95921130T AT95921130T ATE552012T1 AT E552012 T1 ATE552012 T1 AT E552012T1 AT 95921130 T AT95921130 T AT 95921130T AT 95921130 T AT95921130 T AT 95921130T AT E552012 T1 ATE552012 T1 AT E552012T1
Authority
AT
Austria
Prior art keywords
antagonists
inhibition
active substance
abnormal growth
synovial cells
Prior art date
Application number
AT95921130T
Other languages
English (en)
Inventor
Tadamitsu Kishimoto
Masahiko Mihara
Yoichiro Moriya
Yoshiyuki Ohsugi
Original Assignee
Chugai Pharmaceutical Co Ltd
Tadamitsu Kishimoto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17112746&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE552012(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd, Tadamitsu Kishimoto filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE552012T1 publication Critical patent/ATE552012T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT95921130T 1994-10-07 1995-06-07 Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff ATE552012T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP24403594 1994-10-07
PCT/JP1995/001144 WO1996011020A1 (en) 1994-10-07 1995-06-07 Rheumatoid arthritis remedy containing il-6 antagonist as active ingredient

Publications (1)

Publication Number Publication Date
ATE552012T1 true ATE552012T1 (de) 2012-04-15

Family

ID=17112746

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95921130T ATE552012T1 (de) 1994-10-07 1995-06-07 Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff

Country Status (18)

Country Link
EP (3) EP2107070A1 (de)
JP (1) JP3067987B2 (de)
KR (1) KR100306517B1 (de)
CN (2) CN101361972B (de)
AT (1) ATE552012T1 (de)
AU (1) AU700819B2 (de)
CA (1) CA2201781C (de)
CZ (1) CZ296919B6 (de)
DK (1) DK0783893T3 (de)
ES (1) ES2384222T3 (de)
FI (1) FI120721B (de)
HU (1) HU223602B1 (de)
LU (1) LU92048I2 (de)
NO (4) NO321089B1 (de)
PL (1) PL186506B1 (de)
PT (1) PT783893E (de)
RU (1) RU2147443C1 (de)
WO (1) WO1996011020A1 (de)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736282B2 (en) * 1997-03-21 2001-07-26 Chugai Seiyaku Kabushiki Kaisha A preventive or therapeutic agent for sensitized T cell- mediated diseases comprising IL-6 antagonist as an active ingredient
EP1004315B1 (de) * 1997-08-15 2008-05-21 Chugai Seiyaku Kabushiki Kaisha Präventiva oder arzneien enthaltend neutralisierende anti-il6-rezeptor antikörper zur reduktion urinären proteins bei systemischen lupus erythematosus
PT1074268E (pt) 1998-03-17 2008-02-28 Chugai Pharmaceutical Co Ltd Agentes profilácticos ou terapêuticos para doenças intestinais inflamatórias contendo anticorpos antagonistas do receptor il-6
WO1999054478A1 (en) 1998-04-17 1999-10-28 Suntory Limited Gene encoding protein having aurone synthesizing activity
WO2002034292A1 (fr) 2000-10-25 2002-05-02 Chugai Seiyaku Kabushiki Kaisha Agents preventifs ou therapeutiques contre le psoriasis renfermant l'antagoniste de l'il-6 comme substance active
WO2002066063A1 (en) * 2001-02-23 2002-08-29 Nippon Organon K.K. Remedies for metabolic bone diseases
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
KR100881900B1 (ko) * 2001-04-05 2009-02-04 가부시키가이샤 멘에키세이부츠 켄큐죠 항-오스테오폰틴 항체 및 그 용도
WO2003068259A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
JP2007104901A (ja) * 2004-01-16 2007-04-26 Astellas Pharma Inc 関節リウマチ治療薬のスクリーニング法
BRPI0506679A (pt) * 2004-02-11 2007-05-15 Warner Lambert Co métodos de tratar osteoartrite com antagonistas de il-6
AR048335A1 (es) 2004-03-24 2006-04-19 Chugai Pharmaceutical Co Ltd Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo
RU2293560C2 (ru) * 2005-03-09 2007-02-20 Лидия Николаевна Долгова Способ лечения хронических гонартритов у больных остеоартрозом
RU2293559C2 (ru) * 2005-03-09 2007-02-20 Лидия Николаевна Долгова Способ подготовки к любрикантной терапии
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
JO3058B1 (ar) * 2005-04-29 2017-03-15 Applied Molecular Evolution Inc الاجسام المضادة لمضادات -اي ال-6,تركيباتها طرقها واستعمالاتها
KR20080047564A (ko) * 2005-09-28 2008-05-29 사이토스 바이오테크놀로지 아게 인터루킨-1 컨쥬게이트 및 그의 용도
WO2007043641A1 (ja) 2005-10-14 2007-04-19 Fukuoka University 膵島移植における移植膵島障害抑制剤
BRPI0617664B8 (pt) 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
AU2007208678B2 (en) 2006-01-27 2013-01-10 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for diseases involving choroidal neovascularization
DK2006381T3 (en) 2006-03-31 2016-02-22 Chugai Pharmaceutical Co Ltd PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS
EP2009101B1 (de) 2006-03-31 2017-10-25 Chugai Seiyaku Kabushiki Kaisha Antikörpermodifikationsverfahren für die aufreinigung eines bispezifischen antikörpers
WO2007116962A1 (ja) 2006-04-07 2007-10-18 Osaka University 筋再生促進剤
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
CA2657763C (en) 2006-08-03 2016-05-31 Vaccinex Inc. Anti-il-6 monoclonal antibodies and uses thereof
JP2010095445A (ja) * 2006-12-27 2010-04-30 Tokyo Medical & Dental Univ Ｉｌ−６アンタゴニストを有効成分とする炎症性筋疾患治療剤
CN101646459B (zh) 2007-01-23 2014-02-12 国立大学法人信州大学 慢性排斥反应抑制剂
ES2687808T3 (es) 2007-09-26 2018-10-29 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
RU2505603C2 (ru) 2007-09-26 2014-01-27 Чугаи Сейяку Кабусики Кайся Антитело против рецептора il-6
DK2202245T3 (en) 2007-09-26 2016-11-21 Chugai Pharmaceutical Co Ltd A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR
MX337081B (es) 2007-12-05 2016-02-10 Chugai Pharmaceutical Co Ltd Anticuerpo anti-nr10 y su uso.
PT2708559T (pt) 2008-04-11 2018-05-16 Chugai Pharmaceutical Co Ltd Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio
US8034344B2 (en) 2008-05-13 2011-10-11 Novimmune S.A. Anti-IL-6/IL-6R antibodies and methods of use thereof
JP5544290B2 (ja) * 2008-06-05 2014-07-09 独立行政法人国立がん研究センター 神経浸潤抑制剤
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
MX2011012136A (es) 2009-05-15 2012-04-10 Chugai Pharmaceutical Co Ltd Anticuerpo anti-axl.
JP6049455B2 (ja) * 2009-05-18 2016-12-21 ザ ユニバーシティ オブ ホンコンＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ｈｏｎｇ Ｋｏｎｇ 炎症性関節炎を治療するための組成物および方法
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
TWI505838B (zh) 2010-01-20 2015-11-01 Chugai Pharmaceutical Co Ltd Stabilized antibody solution containing
EP2543730B1 (de) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Variante einer konstanten antikörperregion
HUE060454T2 (hu) 2010-05-28 2023-03-28 Chugai Pharmaceutical Co Ltd Daganatellenes T-sejt-választ fokozó szer
EP2578233B1 (de) 2010-05-28 2017-04-26 National Cancer Center Therapeutischer wirkstoff gegen bauchspeicheldrüsenkrebs
EP4029881A1 (de) 2010-11-08 2022-07-20 F. Hoffmann-La Roche AG Subkutan verabreichter anti-il-6-rezeptorantikörper
TR201802772T4 (tr) 2010-11-17 2018-03-21 Chugai Pharmaceutical Co Ltd Kan pıhtılaşma faktörü VIII in işlevi için alternatif işleve sahip multi-spesifik antijen bağlayıcı molekül.
MX365235B (es) 2010-11-30 2019-05-28 Chugai Pharmaceutical Co Ltd Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno.
JP4987117B2 (ja) 2010-12-27 2012-07-25 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤
EP3604330A1 (de) 2011-02-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Fcgammariib-spezifischer fc-antikörper
TW201326209A (zh) 2011-09-30 2013-07-01 Chugai Pharmaceutical Co Ltd 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
EP2762493B1 (de) 2011-09-30 2021-06-09 Chugai Seiyaku Kabushiki Kaisha Antigenbindende moleküle zur förderung der zersetzung von antigenen mit mehreren biologischen aktivitäten
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
WO2013087911A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
JP6117915B2 (ja) 2012-05-21 2017-04-19 コリア リサーチ インスティテュート オブ バイオサイエンス アンド バイオテクノロジーＫｏｒｅａ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ Ｏｆ Ｂｉｏｓｃｉｅｎｃｅ Ａｎｄ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ ミゾコウジュの抽出物またはその分画物を有効成分として含む、ｓｔａｔ３媒介性疾患の予防または治療用医薬組成物
EP3009518B1 (de) 2013-06-11 2020-08-12 National Center of Neurology and Psychiatry Verfahren zur vorhersage einer posttherapeutischen prognose von patienten mit schubförmig remittierender multipler sklerose (rrms) und verfahren zur bestimmung der anwendbarkeit der neuartigen therapie
ES2881306T3 (es) 2013-09-27 2021-11-29 Chugai Pharmaceutical Co Ltd Método para la producción de heteromultímeros de polipéptidos
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
HUE056489T2 (hu) 2014-12-19 2022-02-28 Chugai Pharmaceutical Co Ltd Anti-C5 antitestek és alkalmazási eljárások
SG11201706014PA (en) 2015-02-05 2017-08-30 Chugai Pharmaceutical Co Ltd Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
SG11201705093UA (en) 2015-02-27 2017-07-28 Chugai Pharmaceutical Co Ltd Composition for treating il-6-related diseases
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JP6875683B2 (ja) 2015-05-19 2021-05-26 国立研究開発法人国立精神・神経医療研究センター 多発性硬化症（ｍｓ）患者の新規治療適用判断方法
WO2016195088A1 (ja) 2015-06-04 2016-12-08 国立研究開発法人 国立精神・神経医療研究センター Ｉｌ－６阻害剤を有効成分とする精神疾患治療剤
TWI729022B (zh) 2015-11-03 2021-06-01 法商賽諾菲生物技術公司 用於治療葡萄膜炎及黃斑水腫之包含ｉｌ６ｒ抗體的組合物與其使用方法
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
JP7219005B2 (ja) 2015-12-28 2023-02-07 中外製薬株式会社 Ｆｃ領域含有ポリペプチドの精製を効率化するための方法
EP3431102A4 (de) 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha Zellschadeninduzierendes therapeutisches arzneimittel zur verwendung in der krebstherapie
JP7320943B2 (ja) 2016-04-28 2023-08-04 中外製薬株式会社 抗体含有製剤
KR102538749B1 (ko) 2016-08-05 2023-06-01 추가이 세이야쿠 가부시키가이샤 Il-8 관련 질환의 치료용 또는 예방용 조성물
CN108339118A (zh) * 2017-01-23 2018-07-31 瑞阳(苏州)生物科技有限公司 治疗或预防阻塞性睡眠呼吸暂停的药物组合物
JP7185884B2 (ja) 2017-05-02 2022-12-08 国立研究開発法人国立精神・神経医療研究センター Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法
RU2020111737A (ru) 2017-09-13 2021-10-13 Цзянсу Хэнжуй Медицин Ко., Лтд. Антитело против il-6r и его антигенсвязывающий фрагмент и медицинское применение
EP3698808B1 (de) 2017-10-20 2025-01-01 Hyogo College Of Medicine Anti-il-6 rezeptorantikörper enthaltende medizinische zusammensetzung zur verhinderung von postoperativer adhäsion
AU2018361430B2 (en) 2017-11-01 2025-08-14 Chugai Seiyaku Kabushiki Kaisha Antibody variant and isoform with lowered biological activity
MX2021002422A (es) 2018-08-29 2021-07-15 Regeneron Pharma Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide.
CN109517064B (zh) * 2018-10-10 2020-05-08 北京汇智和源生物技术有限公司 白介素-6的人源化单克隆抗体、其编码基因及应用
EP3917618A1 (de) 2019-01-31 2021-12-08 Sanofi Biotechnology Anti-il-6-rezeptor-antikörper zur behandlung von juveniler idiopathischer arthritis
WO2020178193A1 (en) 2019-03-01 2020-09-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Method of treatment of sarcoidosis
EP3959240A1 (de) 2019-04-24 2022-03-02 Sanofi Biotechnology Verfahren zur diagnose und behandlung von rheumatoider arthritis
AU2020288561A1 (en) 2019-06-04 2021-12-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating pain in subjects with rheumatoid arthritis

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171840A (en) 1988-01-22 1992-12-15 Tadamitsu Kishimoto Receptor protein for human B cell stimulatory factor-2
EP0399429A1 (de) * 1989-05-22 1990-11-28 Toray Industries, Inc. Monoklonaler Antikörper gegen menschliches Interleukin-6
DE69029015T2 (de) * 1989-07-20 1998-01-22 Tadamitsu Kishimoto Antikörper gegen menschlichen Interleukin-6-Rezeptor
JP2898064B2 (ja) 1989-08-03 1999-05-31 忠三 岸本 ヒトｇｐ１３０蛋白質
DE3939706C1 (de) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
WO1991007986A1 (en) * 1989-12-04 1991-06-13 Schering Corporation Method of treating septic shock
JP2898040B2 (ja) 1990-01-26 1999-05-31 忠三 岸本 ｇｐ１３０蛋白質に対する抗体
US5210075A (en) 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
JPH0489433A (ja) 1990-07-27 1992-03-23 Hitachi Chem Co Ltd 免疫調節剤
JP2947924B2 (ja) * 1990-11-21 1999-09-13 信和化工株式会社 光学異性体用分離剤
JPH04187645A (ja) 1990-11-22 1992-07-06 Chuzo Kishimoto インターロイキン―６作用抑制剤
US5795965A (en) * 1991-04-25 1998-08-18 Chugai Seiyaku Kabushiki Kaisha Reshaped human to human interleukin-6 receptor
JPH05300338A (ja) 1992-04-17 1993-11-12 Ricoh Co Ltd 複合機
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
FR2694767B1 (fr) * 1992-08-13 1994-10-21 Innotherapie Lab Sa Anticorps monoclonaux anti-IL6R, et leurs applications.
JPH06134617A (ja) 1992-10-23 1994-05-17 Amada Co Ltd 鋸盤の鋸刃テンション自動調整装置
JP3525221B2 (ja) * 1993-02-17 2004-05-10 味の素株式会社 免疫抑制剤

Also Published As

Publication number Publication date
AU700819B2 (en) 1999-01-14
NO321089B1 (no) 2006-03-13
CN101361972A (zh) 2009-02-11
NO971546L (no) 1997-06-04
EP0783893A1 (de) 1997-07-16
DK0783893T3 (da) 2012-05-29
ES2384222T3 (es) 2012-07-02
JPH08208514A (ja) 1996-08-13
EP2107070A1 (de) 2009-10-07
CN101361972B (zh) 2011-05-25
CA2201781C (en) 2010-01-12
NO2009009I1 (no) 2009-05-11
FI971404A0 (fi) 1997-04-04
AU2630395A (en) 1996-05-02
PT783893E (pt) 2012-05-24
CN101601861A (zh) 2009-12-16
FI120721B (fi) 2010-02-15
RU2147443C1 (ru) 2000-04-20
PL319574A1 (en) 1997-08-18
CA2201781A1 (en) 1996-04-18
JP3067987B2 (ja) 2000-07-24
CZ103497A3 (en) 1997-08-13
NO971546D0 (no) 1997-04-04
WO1996011020A1 (en) 1996-04-18
EP0783893B1 (de) 2012-04-04
EP2077120A3 (de) 2009-07-15
PL186506B1 (pl) 2004-01-30
NO2009009I2 (no) 2013-03-18
HUT77036A (hu) 1998-03-02
FI971404L (fi) 1997-06-03
HK1127497A1 (en) 2009-09-25
NO2018017I1 (no) 2018-05-23
EP2077120A2 (de) 2009-07-08
KR100306517B1 (ko) 2001-11-30
HU223602B1 (hu) 2004-10-28
EP0783893A4 (de) 1998-04-22
LU92048I2 (fr) 2012-09-20
CZ296919B6 (cs) 2006-07-12
NO20055446L (no) 1997-06-04

Similar Documents

Publication Publication Date Title
ATE552012T1 (de) Hemmung des abnormalen wachstums von synovialzellen durch il-6-antagonisten als wirkstoff
RU97108276A (ru) Лечебные средства против хронического ревматоидного артрита, содержащие антагонист il-6 в качестве эффективного компонента
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
BR9907256A (pt) Inibidores beta-cetoamida de proteassoma 20s
RU94040174A (ru) Гетероциклические соединения, способ их получения, фармкомпозиция и способ лечения
ATE232204T1 (de) Neue sulfonamide
TR200200082T2 (tr) MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi.
TR199801253T2 (xx) Vitronektin resept�r� antagonistleri.
NO924326L (no) Antitrombosemidler
ATE387215T1 (de) Mittel zur prävention oder behandlung von psoriasis mit einem il-6-antagonist als wirkstoff
DE59209986D1 (de) Imidazo-annellierte Iso- und Heterocyclen, Antagonisten als Angiotensin II
BR9910359A (pt) Proteìna hìbrida para inibição de desgranulação de mastócitos e seu uso
KR960013371A (ko) 약학적 혼합물
EA200000891A1 (ru) Кристаллическая форма 4-[5-метил-3-фенилизоксазол-4-ил] бензолсульфонамида
DE69942063D1 (de) Antagonisten von 'hedgehog' und 'patched' zur inhibierung des wachstums und der differenzierung von zellen und geweben, als auch deren verwendungen
EA200100607A1 (ru) 3,4,5-тризамещенные арилнитроны и содержащие их фармацевтические композиции
ES2152328T3 (es) Antagonistas del receptor del fibrinogeno.
DK0636247T3 (da) Fremgangsmåde og sammensætning til reduktion af virkningerne af endogen alkalisk phosphatase
DK0732926T3 (da) Farmaceutisk formulering til profylakse eller forbehandling af forgiftninger fremkaldt af organophosphor-cholinesterase-inhibitorer
ES2044100T3 (es) Ciertas combinaciones de antagonistas del "paf" y antihistaminicos y metodos.
EA199700223A1 (ru) Бициклические антагонисты тахикининов, их получение и применение в фармацевтической композиции
DE3578125D1 (de) Formulierung von entzuendungshemmenden arzneimitteln.
DK435089A (da) Anvendelse af zofenopril til behandling af rheumatoid arthritis
IT1274022B (it) Derivati della cumarina ad attivita' farmacologica, loro uso e composizioni farmaceutiche che li contengono
ES2038703T3 (es) Procedimiento para la determinacion de inhibidor de la proteina c.